

Shawn J Skerrett

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6999729/shawn-j-skerrett-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17
papers

449
citations

9
h-index

21
g-index

76
ext. papers

573
ext. citations

7.8
avg, IF

3.36
L-index

#	Paper	IF	Citations
17	Update on the Features and Measurements of Experimental Acute Lung Injury in Animals: An Official American Thoracic Society Workshop Report.. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022 , 66, e1-e14	5.7	5
16	HDAC3 inhibitor RGFP966 controls bacterial growth and modulates macrophage signaling during Mycobacterium tuberculosis infection. <i>Tuberculosis</i> , 2021 , 127, 102062	2.6	1
15	Glycated Albumin Triggers an Inflammatory Response in the Human Airway Epithelium and Causes an Increase in Ciliary Beat Frequency. <i>Frontiers in Physiology</i> , 2021 , 12, 653177	4.6	1
14	A macrophage-targeted platform for extending drug dosing with polymer prodrugs for pulmonary infection prophylaxis. <i>Journal of Controlled Release</i> , 2021 , 330, 284-292	11.7	2
13	Tn-Seq reveals hidden complexity in the utilization of host-derived glutathione in Francisella tularensis. <i>PLoS Pathogens</i> , 2020 , 16, e1008566	7.6	4
12	Nicotinamide Limits Replication of Mycobacterium tuberculosis and Bacille Calmette-Guérin Within Macrophages. <i>Journal of Infectious Diseases</i> , 2020 , 221, 989-999	7	4
11	MEK1 regulates pulmonary macrophage inflammatory responses and resolution of acute lung injury. <i>JCI Insight</i> , 2019 , 4,	9.9	4
10	Recent advances in nontuberculous mycobacterial lung infections. <i>F1000Research</i> , 2019 , 8,	3.6	12
9	Glycan targeted polymeric antibiotic prodrugs for alveolar macrophage infections. <i>Biomaterials</i> , 2019 , 195, 38-50	15.6	26
8	A Phosphatidylinositol 3-Kinase Effector Alters Phagosomal Maturation to Promote Intracellular Growth of Francisella. <i>Cell Host and Microbe</i> , 2018 , 24, 285-295.e8	23.4	29
7	Macrophage-targeted drugamers with enzyme-cleavable linkers deliver high intracellular drug dosing and sustained drug pharmacokinetics against alveolar pulmonary infections. <i>Journal of Controlled Release</i> , 2018 , 287, 1-11	11.7	32
6	Cytometry TOF identifies alveolar macrophage subtypes in acute respiratory distress syndrome. <i>JCI Insight</i> , 2018 , 3,	9.9	26
5	Synthetic Macromolecular Antibiotic Platform for Inhalable Therapy against Aerosolized Intracellular Alveolar Infections. <i>Molecular Pharmaceutics</i> , 2017 , 14, 1988-1997	5.6	16
4	Toll-like receptor 2 has a prominent but nonessential role in innate immunity to pneumonia. <i>Physiological Reports</i> , 2017 , 5, e13491	2.6	7
3	Prior infection with Type A Francisella tularensis antagonizes the pulmonary transcriptional response to an aerosolized Toll-like receptor 4 agonist. <i>BMC Genomics</i> , 2015 , 16, 874	4.5	9
2	Redundant Toll-like receptor signaling in the pulmonary host response to Pseudomonas aeruginosa. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007 , 292, L312-22	5.8	108
1	Cutting edge: myeloid differentiation factor 88 is essential for pulmonary host defense against Pseudomonas aeruginosa but not Staphylococcus aureus. <i>Journal of Immunology</i> , 2004 , 172, 3377-81	5.3	160

